Durvalumab as a maintenance therapy after a definitive chemoradiotherapy for a stage III non-small cell lung cancer - an interim analysis of the PACIFIC trial

被引：0
|
作者：
Kawecki, Maciej [1 ]
机构：
[1] Maria Sklodowska Curie Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2018年 / 14卷 / 03期
关键词：
D O I：
10.5603/OCP.2018.0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 170
页数：4
相关论文
共 50 条
  • [31] Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system
    Armijo, Nicolas
    Salas, Constanza
    Espinoza, Nazareth
    Espinoza, Manuel
    Balmaceda, Carlos
    PLOS ONE, 2024, 19 (07):
  • [32] Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer
    Sankar, Kamya
    Bryant, Alex K.
    Strohbehn, Garth W.
    Zhao, Lili
    Elliott, David
    Moghanaki, Drew
    Kelley, Michael J.
    Ramnath, Nithya
    Green, Michael D.
    CANCERS, 2022, 14 (03)
  • [33] Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
    Murata, S.
    Horinouchi, H.
    Morishita, M.
    Kaku, S.
    Shinno, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Yamamoto, N.
    Okuma, K.
    Kusumoto, M.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1555 - S1555
  • [34] Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
    Senan, S.
    Ozguroglu, M.
    Daniel, D.
    Villegas, A.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Faivre-Finn, C.
    Paz-Ares, L.
    Wu, Y. L.
    Mann, H.
    Dennis, P. A.
    Antonia, S. J.
    ESMO OPEN, 2022, 7 (02)
  • [35] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
  • [36] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Kazutaka Hosoya
    Daichi Fujimoto
    Hayato Kawachi
    Yuki Sato
    Mariko Kogo
    Kazuma Nagata
    Atsushi Nakagawa
    Ryo Tachikawa
    Shinya Hiraoka
    Masaki Kokubo
    Keisuke Tomii
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 275 - 280
  • [37] Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
    Jung, Hyun Ae
    Noh, Jae Myoung
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Pyo, Hongryull
    Ahn, Yong Chan
    Park, Keunchil
    LUNG CANCER, 2020, 146 : 23 - 29
  • [38] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Hosoya, Kazutaka
    Fujimoto, Daichi
    Kawachi, Hayato
    Sato, Yuki
    Kogo, Mariko
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Hiraoka, Shinya
    Kokubo, Masaki
    Tomii, Keisuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 275 - 280
  • [39] Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer
    Katsui, Kuniaki
    Ogata, Takeshi
    Tada, Akihiro
    Sugiyama, Soichi
    Yoshio, Kotaro
    Kuroda, Masahiro
    Kiura, Katsuyuki
    Maeda, Yoshinobu
    Toyooka, Shinichi
    Hiraki, Takao
    Kanazawa, Susumu
    ACTA MEDICA OKAYAMA, 2021, 75 (01) : 15 - 23
  • [40] Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer
    Jang, Bum-Sup
    Cha, Myung-Jin
    Kim, Hak Jae
    Oh, Seil
    Wu, Hong-Gyun
    Kim, Eunji
    Kim, Byoung Hyuck
    Kim, Jae Sik
    Chang, Ji Hyun
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : 126 - 132
12345